Coumarins and indandiones

Overview
Coumarins and indandiones are two related classes of oral anticoagulants that act as vitamin K antagonists (VKAs). They inhibit the synthesis of vitamin K–dependent clotting factors (II, VII, IX, and X) and the anticoagulant proteins C and S in the liver, leading to reduced blood coagulation. While coumarins (e.g., warfarin, acenocoumarol, phenprocoumon) remain in clinical use globally, indandiones (e.g., phenindione) are now rarely used due to a higher incidence of adverse reactions, especially hypersensitivity and hepatotoxicity.

Mechanism of Action

• Both classes inhibit the enzyme vitamin K epoxide reductase complex 1 (VKORC1).

• This prevents the regeneration of reduced vitamin K, which is required as a cofactor for γ-carboxylation of glutamic acid residues on clotting factors II, VII, IX, and X.

• The result is the production of biologically inactive clotting factors, impairing the coagulation cascade.

• The onset of action is delayed (usually 24–72 hours) because existing active clotting factors must degrade before full anticoagulant effect is achieved.

Therapeutic Uses

• Prevention and treatment of venous thromboembolism (VTE)

• Prevention of stroke and systemic embolism in atrial fibrillation

• Prevention and treatment of pulmonary embolism

• Prophylaxis in patients with mechanical prosthetic heart valves

• Secondary prevention after myocardial infarction (in selected patients)

Commonly Used Agents

• Coumarins: Warfarin (Coumadin, Marevan), Acenocoumarol (Sintrom), Phenprocoumon (Marcoumar)

• Indandiones: Phenindione (Dindevan) – limited/rare use due to safety profile

Dosage and Administration

• Warfarin: Initial dose typically 2–5 mg once daily, adjusted according to INR (target usually 2.0–3.0 for most indications, 2.5–3.5 for mechanical heart valves)

• Acenocoumarol: Usually 1–4 mg daily, titrated by INR

• Phenprocoumon: Longer half-life allows less frequent dose adjustment; dose individualized by INR

• Phenindione: Starting dose often 50–100 mg, reduced to maintenance 25–75 mg daily, but rarely prescribed today

Contraindications

• Active bleeding or high bleeding risk

• Recent major surgery with high risk of bleeding

• Pregnancy (especially first trimester and near term – teratogenic and risk of fetal bleeding)

• Severe uncontrolled hypertension

• Severe hepatic impairment

• Non-compliance with monitoring requirements

Precautions

• Requires regular INR monitoring to maintain therapeutic range

• Dose adjustments needed for changes in diet (vitamin K intake), illness, or concomitant medications

• Increased sensitivity in elderly, malnourished, or liver-impaired patients

Adverse Effects

• Common: Bleeding, easy bruising

• Serious: Intracranial hemorrhage, gastrointestinal bleeding, retroperitoneal bleeding

• Specific to indandiones: Higher risk of rash, fever, agranulocytosis, hepatitis, nephritis

• Rare: Warfarin-induced skin necrosis, purple toe syndrome

Drug Interactions

• Potentiation of effect (↑ INR/bleeding risk): Amiodarone, macrolides, fluoroquinolones, azole antifungals, metronidazole, TMP-SMX, SSRIs, NSAIDs, alcohol (acute use)

• Reduction of effect (↓ INR/clotting risk): Rifampicin, carbamazepine, phenytoin (chronic use), barbiturates, vitamin K–rich foods, alcohol (chronic use)

• Additive bleeding risk: Antiplatelet drugs (aspirin, clopidogrel), other anticoagulants, NSAIDs

Monitoring

• Regular INR testing (initially daily or every few days, then weekly, then every 2–4 weeks once stable)

• Clinical monitoring for bleeding/bruising or signs of thrombosis

• Adjustment based on INR target specific to the indication

Reversal of Anticoagulation

• Non-urgent: Withholding doses, administering oral vitamin K (phytonadione)

• Urgent/major bleeding: Intravenous vitamin K plus prothrombin complex concentrate (PCC) or fresh frozen plasma (FFP)

Comparative Notes: Coumarins vs. Indandiones

Feature	Coumarins (e.g., warfarin)	Indandiones (e.g., phenindione)
Clinical use	Widely used worldwide	Rarely used, largely replaced
Safety profile	Well-studied, predictable with INR monitoring	More unpredictable, higher risk of hypersensitivity, hepatic injury
Half-life	Warfarin ~36–42 h	Phenindione ~5–15 h (shorter)
Dosing frequency	Once daily	Once or twice daily
Market availability	Widely available	Limited availability in select countries
Guidelines	Endorsed in all major anticoagulation guidelines	Generally not recommended unless coumarins unsuitable